Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on March 15, 2017. The filing reports financial results for the fourth quarter and the full year ended December 31, 2016. The company is incorporated in Delaware and headquartered in Livonia, Michigan.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing text does not detail specific material changes versus prior periods. It serves solely as a notification that the results for the fourth quarter and year ended December 31, 2016, have been issued via press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document explicitly states that the information is furnished pursuant to Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Gemphire Therapeutics Inc., as the input metadata incorrectly listed "Metavia Inc."
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2016.
- Confirm the filing date of March 15, 2017, aligns with the release of the 2016 annual results.
- Note that this 8-K is a notification of results rather than a detailed financial statement itself.